These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25700378)

  • 1. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion.
    Sotgiu G; Matteelli A; Getahun H; Girardi E; Sañé Schepisi M; Centis R; Migliori GB
    Eur Respir J; 2015 Apr; 45(4):1170-3. PubMed ID: 25700378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practice guideline for treatment of latent tuberculosis infection in children.
    Nicholson EG; Geltemeyer AM; Smith KC
    J Pediatr Health Care; 2015; 29(3):302-7. PubMed ID: 25792195
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of latent tuberculosis infection].
    Bouvet E
    Rev Prat; 2012 Apr; 62(4):498-9. PubMed ID: 22641889
    [No Abstract]   [Full Text] [Related]  

  • 4. Latent Mycobacterium tuberculosis infection.
    Getahun H; Matteelli A; Chaisson RE; Raviglione M
    N Engl J Med; 2015 May; 372(22):2127-35. PubMed ID: 26017823
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 6. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards better management of latent tuberculosis infection in children and young adults in the Maghreb. Conclusions of an expert meeting, Paris, 16 March 2018.
    Delacourt C; Zellweger JP;
    Arch Pediatr; 2019 Feb; 26(2):126-129. PubMed ID: 30642745
    [No Abstract]   [Full Text] [Related]  

  • 9. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.
    Marks SM; Dowdy DW; Menzies NA; Shete PB; Salomon JA; Parriott A; Shrestha S; Flood J; Hill AN
    Public Health Rep; 2020; 135(1_suppl):38S-43S. PubMed ID: 32735183
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present-day treatment of tuberculosis and latent tuberculosis infection.
    Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Management of Latent Tuberculosis Infection.
    Muñoz L; Stagg HR; Abubakar I
    Cold Spring Harb Perspect Med; 2015 Jun; 5(11):. PubMed ID: 26054858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence.
    Saukkonen JJ; Powell K; Jereb JA
    Am J Respir Crit Care Med; 2012 Mar; 185(6):598-9. PubMed ID: 22422902
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016.
    Schmit KM; Wortham JM; Ho CS; Powell KM
    Clin Infect Dis; 2020 Dec; 71(9):2502-2505. PubMed ID: 32185390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis.
    Kelly AM
    Nurs Clin North Am; 2019 Jun; 54(2):193-205. PubMed ID: 31027661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic.
    Gaensbauer J; Aiona K; Haas M; Reves R; Young J; Belknap R
    Pediatr Infect Dis J; 2018 Mar; 37(3):224-228. PubMed ID: 28777204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clarifications to the consensus document on the diagnosis, treatment and prevention of tuberculosis].
    Peña JM
    Enferm Infecc Microbiol Clin; 2011 Feb; 29(2):162-3; author reply 163-4. PubMed ID: 20888083
    [No Abstract]   [Full Text] [Related]  

  • 19. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Assefa Y; Assefa Y; Woldeyohannes S; Hamada Y; Getahun H
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in diagnosis and treatment of latent tuberculosis infection.
    Gupta KB
    Indian J Tuberc; 2012 Jan; 59(1):1-5. PubMed ID: 22670504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.